7月28日早盘,港股恒瑞医药(06088.HK)以10%的高开涨幅点燃市场热情,截至发稿前已涨超16%。至此,从今年5月下旬上市以来累计涨幅已达80%。这场资本狂欢的导火索,是前一日恒瑞医药发布的一纸合作协议:公司将HRS-9821项目的全球独家权利,以及至多11个项目的独家许可选择权,有偿授权给全球制药巨头GSK。5亿美元首付款、120亿美元潜在里程碑付款、分梯度销售提成、开创性规模化合作计划…...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.